Marino Stram & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Marino Stram & Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-396	Closed	-$208K	–	194
2025 Q2	$208K	Buy	396 +20	+5%	+$11.2K	0.04%	171
2025 Q1	$239K	Hold	376	–	–	0.05%	150
2024 Q4	$268K	Buy	376 +4	+1%	+$3.36K	0.06%	143
2024 Q3	$391K	Hold	372	–	–	0.09%	122
2024 Q2	$391K	Hold	372	–	–	0.1%	113
2024 Q1	$358K	Hold	372	–	–	0.08%	124
2023 Q4	$327K	Hold	372	–	–	0.08%	129
2023 Q3	$306K	Sell	372 -7	-2%	-$5.5K	0.09%	125
2023 Q2	$272K	Hold	379	–	–	0.08%	133
2023 Q1	$311K	Hold	379	–	–	0.09%	122
2022 Q4	$273K	Hold	379	–	–	0.09%	124
2022 Q3	$261K	Sell	379 -45	-11%	-$28.3K	0.09%	120
2022 Q2	$251K	Hold	424	–	–	0.09%	125
2022 Q1	$296K	Hold	424	–	–	0.09%	125
2021 Q4	$268K	Hold	424	–	–	0.08%	130
2021 Q3	$257K	Buy	+424	New	+$263K	0.09%	126

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Marino Stram & Associates's REGN Position: Q3 2025 in Review

Marino Stram & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 396 shares — an estimated $208K sold.

Marino Stram & Associates first reported a position in REGN in Q3 2021 and held it in 16 quarters. The position peaked at $391K in Q3 2024. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Marino Stram & Associates reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Marino Stram & Associates sold 396 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $208K.
Marino Stram & Associates first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 16 quarters.
Marino Stram & Associates's Regeneron Pharmaceuticals position peaked at $391K in Q3 2024.
1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Marino Stram & Associates's 13F filing for Q3 2025, filed 3 Nov 2025.